1. Home
  2. ASAN vs ADMA Comparison

ASAN vs ADMA Comparison

Compare ASAN & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Asana Inc.

ASAN

Asana Inc.

HOLD

Current Price

$6.97

Market Cap

3.4B

Sector

Technology

ML Signal

HOLD

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$15.08

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASAN
ADMA
Founded
2008
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.6B
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
ASAN
ADMA
Price
$6.97
$15.08
Analyst Decision
Hold
Strong Buy
Analyst Count
14
2
Target Price
$12.62
$28.50
AVG Volume (30 Days)
5.6M
3.2M
Earning Date
06-01-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
5.13
N/A
EPS
N/A
0.60
Revenue
$723,876,000.00
$42,219,783.00
Revenue This Year
$10.53
$27.46
Revenue Next Year
$9.03
$21.11
P/E Ratio
N/A
$25.01
Revenue Growth
10.94
43.85
52 Week Low
$6.51
$13.76
52 Week High
$19.00
$25.67

Technical Indicators

Market Signals
Indicator
ASAN
ADMA
Relative Strength Index (RSI) 33.99 38.61
Support Level $6.51 $14.19
Resistance Level $8.20 $16.28
Average True Range (ATR) 0.45 0.83
MACD 0.11 -0.03
Stochastic Oscillator 23.01 17.62

Price Performance

Historical Comparison
ASAN
ADMA

About ASAN Asana Inc.

Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Share on Social Networks: